Buspirone and lorazepam abuse liability in humans: Behavioral effects, subjective effects and choice

J. R. Troisi, T. S. Critchfield, Roland R Griffiths

Research output: Contribution to journalArticle

Abstract

This study compared behavioral and subjective effects of two anxiolytics, the benzodiazepine lorazepam and the azaspirodecanedione buspirone, in healthy male volunteers with histories of sedative drug abuse. Placebo, lorazepam (1, 2, 4, 8 mg/70 kg) and buspirone (15, 30, 60, 120 mg/70 kg) were administered p.o. in a mixed sequence in a double-blind, cross-over design. Lorazepam, but not buspirone, decreased psychomotor/cognitive performance. Both drugs produced similar increases in ratings of drug strength, however the onset and offset times for lorazepam were later than for buspirone. Lorazepam increased ratings of liking in contrast to buspirone which produced negative mood-related subjective effects (e.g. increases in ratings of disliking, bad/unpleasant effects, and tension-anxiety). Lorazepam was categorized by subjects as producing effects similar to barbiturates or benzodiazepines in contrast to buspirone which was not. When subjects were given a choice between self-administering an intermediate dose of lorazepam (4 mg/70 kg) or buspirone (60 mg/70 kg), which produced similar ratings of drug strength, eight out of nine subjects chose lorazepam. This study provides the clearest human experimental evidence to date that the abuse liability of buspirone is lower than that of a prototypic benzodiazepine, even at supratherapeutic doses.

Original languageEnglish (US)
Pages (from-to)217-230
Number of pages14
JournalBehavioural Pharmacology
Volume4
Issue number3
StatePublished - 1993

Fingerprint

Buspirone
Lorazepam
Benzodiazepines
Pharmaceutical Preparations
Psychomotor Performance
Barbiturates
Anti-Anxiety Agents
Hypnotics and Sedatives
Cross-Over Studies
Substance-Related Disorders
Healthy Volunteers
Anxiety
Placebos

Keywords

  • abuse liability
  • buspirone
  • choice
  • humans
  • lorazepam
  • performance effects
  • reinforcing effects
  • subjective effects

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Buspirone and lorazepam abuse liability in humans : Behavioral effects, subjective effects and choice. / Troisi, J. R.; Critchfield, T. S.; Griffiths, Roland R.

In: Behavioural Pharmacology, Vol. 4, No. 3, 1993, p. 217-230.

Research output: Contribution to journalArticle

@article{bc65095dd06e40909693eb42db2c17ce,
title = "Buspirone and lorazepam abuse liability in humans: Behavioral effects, subjective effects and choice",
abstract = "This study compared behavioral and subjective effects of two anxiolytics, the benzodiazepine lorazepam and the azaspirodecanedione buspirone, in healthy male volunteers with histories of sedative drug abuse. Placebo, lorazepam (1, 2, 4, 8 mg/70 kg) and buspirone (15, 30, 60, 120 mg/70 kg) were administered p.o. in a mixed sequence in a double-blind, cross-over design. Lorazepam, but not buspirone, decreased psychomotor/cognitive performance. Both drugs produced similar increases in ratings of drug strength, however the onset and offset times for lorazepam were later than for buspirone. Lorazepam increased ratings of liking in contrast to buspirone which produced negative mood-related subjective effects (e.g. increases in ratings of disliking, bad/unpleasant effects, and tension-anxiety). Lorazepam was categorized by subjects as producing effects similar to barbiturates or benzodiazepines in contrast to buspirone which was not. When subjects were given a choice between self-administering an intermediate dose of lorazepam (4 mg/70 kg) or buspirone (60 mg/70 kg), which produced similar ratings of drug strength, eight out of nine subjects chose lorazepam. This study provides the clearest human experimental evidence to date that the abuse liability of buspirone is lower than that of a prototypic benzodiazepine, even at supratherapeutic doses.",
keywords = "abuse liability, buspirone, choice, humans, lorazepam, performance effects, reinforcing effects, subjective effects",
author = "Troisi, {J. R.} and Critchfield, {T. S.} and Griffiths, {Roland R}",
year = "1993",
language = "English (US)",
volume = "4",
pages = "217--230",
journal = "Behavioural Pharmacology",
issn = "0955-8810",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Buspirone and lorazepam abuse liability in humans

T2 - Behavioral effects, subjective effects and choice

AU - Troisi, J. R.

AU - Critchfield, T. S.

AU - Griffiths, Roland R

PY - 1993

Y1 - 1993

N2 - This study compared behavioral and subjective effects of two anxiolytics, the benzodiazepine lorazepam and the azaspirodecanedione buspirone, in healthy male volunteers with histories of sedative drug abuse. Placebo, lorazepam (1, 2, 4, 8 mg/70 kg) and buspirone (15, 30, 60, 120 mg/70 kg) were administered p.o. in a mixed sequence in a double-blind, cross-over design. Lorazepam, but not buspirone, decreased psychomotor/cognitive performance. Both drugs produced similar increases in ratings of drug strength, however the onset and offset times for lorazepam were later than for buspirone. Lorazepam increased ratings of liking in contrast to buspirone which produced negative mood-related subjective effects (e.g. increases in ratings of disliking, bad/unpleasant effects, and tension-anxiety). Lorazepam was categorized by subjects as producing effects similar to barbiturates or benzodiazepines in contrast to buspirone which was not. When subjects were given a choice between self-administering an intermediate dose of lorazepam (4 mg/70 kg) or buspirone (60 mg/70 kg), which produced similar ratings of drug strength, eight out of nine subjects chose lorazepam. This study provides the clearest human experimental evidence to date that the abuse liability of buspirone is lower than that of a prototypic benzodiazepine, even at supratherapeutic doses.

AB - This study compared behavioral and subjective effects of two anxiolytics, the benzodiazepine lorazepam and the azaspirodecanedione buspirone, in healthy male volunteers with histories of sedative drug abuse. Placebo, lorazepam (1, 2, 4, 8 mg/70 kg) and buspirone (15, 30, 60, 120 mg/70 kg) were administered p.o. in a mixed sequence in a double-blind, cross-over design. Lorazepam, but not buspirone, decreased psychomotor/cognitive performance. Both drugs produced similar increases in ratings of drug strength, however the onset and offset times for lorazepam were later than for buspirone. Lorazepam increased ratings of liking in contrast to buspirone which produced negative mood-related subjective effects (e.g. increases in ratings of disliking, bad/unpleasant effects, and tension-anxiety). Lorazepam was categorized by subjects as producing effects similar to barbiturates or benzodiazepines in contrast to buspirone which was not. When subjects were given a choice between self-administering an intermediate dose of lorazepam (4 mg/70 kg) or buspirone (60 mg/70 kg), which produced similar ratings of drug strength, eight out of nine subjects chose lorazepam. This study provides the clearest human experimental evidence to date that the abuse liability of buspirone is lower than that of a prototypic benzodiazepine, even at supratherapeutic doses.

KW - abuse liability

KW - buspirone

KW - choice

KW - humans

KW - lorazepam

KW - performance effects

KW - reinforcing effects

KW - subjective effects

UR - http://www.scopus.com/inward/record.url?scp=0027318842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027318842&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0027318842

VL - 4

SP - 217

EP - 230

JO - Behavioural Pharmacology

JF - Behavioural Pharmacology

SN - 0955-8810

IS - 3

ER -